Xeris Biopharma Holdings, Inc. XERS
10.46 USD +0.11 (+1.06%)
At closeNov 4, 2026, 7:23 PM EST
10.33 -0.13 -1.24%
After hours · Nov 4, 7:23 PM ET
10.15 Day range 10.71
5.25 52-week range 11.42
- YTD
- +33.25%
- 1 year
- +5.66%
Analyst view
Price target (mean) 12.86 +22.9% upside
Now 10.46
- Target (low)
- 8.00
- Target (mean)
- 12.86
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.02667 | 0.01 – 0.04 | 0.00 | 0.0% | 101.68M | +36.7% | 3 |
| Next quarter | 0.03333 | 0.00 – 0.06 | 0.06 | -44.5% | 111.02M | +29.4% | 3 |
| Current year | -0.09 | -0.14 – -0.03 | 0.00 | 0.0% | 387.90M | +32.9% | 3 |
| Next year | 0.19667 | 0.11 – 0.25 | -0.09 | +318.5% | 480.03M | +23.8% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 10, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Aug 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 7, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 29, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 17, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 19, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Aug 8, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 8, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 5, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| May 9, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 7, 2025 | Piper Sandler | Reiterated | Neutral | Neutral |
| Mar 7, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 7, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 7, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 29, 2025 | Jefferies | Reiterated | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 11, 2024 | Piper Sandler | Downgrade | Overweight | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 10, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Mar 28, 2024 | Oppenheimer | Initiated | — | Outperform |
| Mar 7, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 10, 2023 | Piper Sandler | Maintained | Overweight | Overweight |